1. Home
  2. AWRE vs KLRS Comparison

AWRE vs KLRS Comparison

Compare AWRE & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aware Inc.

AWRE

Aware Inc.

HOLD

Current Price

$1.93

Market Cap

44.5M

Sector

Technology

ML Signal

HOLD

Logo Kalaris Therapeutics Inc.

KLRS

Kalaris Therapeutics Inc.

HOLD

Current Price

$8.29

Market Cap

46.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AWRE
KLRS
Founded
1986
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
44.5M
46.0M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
AWRE
KLRS
Price
$1.93
$8.29
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$20.67
AVG Volume (30 Days)
37.5K
172.1K
Earning Date
10-29-2025
02-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$17,428,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2.72
N/A
52 Week Low
$1.37
$2.14
52 Week High
$2.95
$12.90

Technical Indicators

Market Signals
Indicator
AWRE
KLRS
Relative Strength Index (RSI) 37.27 52.21
Support Level $1.80 $9.00
Resistance Level $2.09 $9.45
Average True Range (ATR) 0.10 1.10
MACD -0.01 -0.20
Stochastic Oscillator 30.95 11.58

Price Performance

Historical Comparison
AWRE
KLRS

About AWRE Aware Inc.

Aware Inc is a provider of software and services to the biometrics industry. The company's software products are used in government and commercial biometrics systems to identify or authenticate people. The government applications of biometrics systems include border control, visa applicant screening, law enforcement, national defense, intelligence, secure credentialing, access control, and background checks. Its commercial applications include user authentication for login to mobile devices, computers, networks, and software programs, user authentication for financial transactions and purchases. Its geographical segments include the United States, the United Kingdom, and the Rest of the world, out of which it derives maximum revenue from United States.

About KLRS Kalaris Therapeutics Inc.

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

Share on Social Networks: